Zhuhai Rundu Pharmaceutical (002923.SZ): Approval and Market Launch of Class 1 Innovative Drug Norcoclaurine Hydrochloride Injection Remain Uncertain

Stock News

Feb 02

Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) has issued an announcement regarding significant stock price fluctuations, stating that the company currently possesses a Class 1 innovative chemical drug, Norcoclaurine Hydrochloride Injection (Specification: 2ml:2.5mg), along with its active pharmaceutical ingredient, and the drug evaluation process is proceeding in an orderly manner. Innovative drug development is characterized by long cycles, substantial investment, and high risks; consequently, uncertainties remain regarding whether the drug will ultimately gain market approval, the timeline for any potential approval, and its subsequent production and sales performance post-launch, and it is not expected to significantly impact the company's financial performance in the short term.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1172663165"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172663165\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172663165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172663165","market":"nz","top_or_hot":-1,"title":"Zhuhai Rundu Pharmaceutical (002923.SZ): Approval and Market Launch of Class 1 Innovative Drug Norcoclaurine Hydrochloride Injection Remain Uncertain","media":"Stock News","content":"<p>Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) has issued an announcement regarding significant stock price fluctuations, stating that the company currently possesses a Class 1 innovative chemical drug, Norcoclaurine Hydrochloride Injection (Specification: 2ml:2.5mg), along with its active pharmaceutical ingredient, and the drug evaluation process is proceeding in an orderly manner.\nInnovative drug development is characterized by long cycles, substantial investment, and high risks; consequently, uncertainties remain regarding whether the drug will ultimately gain market approval, the timeline for any potential approval, and its subsequent production and sales performance post-launch, and it is not expected to significantly impact the company's financial performance in the short term.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhuhai Rundu Pharmaceutical (002923.SZ): Approval and Market Launch of Class 1 Innovative Drug Norcoclaurine Hydrochloride Injection Remain Uncertain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhuhai Rundu Pharmaceutical (002923.SZ): Approval and Market Launch of Class 1 Innovative Drug Norcoclaurine Hydrochloride Injection Remain Uncertain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-02 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) has issued an announcement regarding significant stock price fluctuations, stating that the company currently possesses a Class 1 innovative chemical drug, Norcoclaurine Hydrochloride Injection (Specification: 2ml:2.5mg), along with its active pharmaceutical ingredient, and the drug evaluation process is proceeding in an orderly manner.\nInnovative drug development is characterized by long cycles, substantial investment, and high risks; consequently, uncertainties remain regarding whether the drug will ultimately gain market approval, the timeline for any potential approval, and its subsequent production and sales performance post-launch, and it is not expected to significantly impact the company's financial performance in the short term.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1172663165","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172663165","pubTimestamp":1770033501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) has issued an announcement regarding significant stock price fluctuations, stating that the company currently possesses a Class 1 innovative chemical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK0239":"医药制造","BK1161":"生物科技","06978":"永泰生物-B","BK1574":"生物医药B类股","002923":"润都股份"},"translate_title":"珠海润都制药（002923.SZ）：1类创新药盐酸去甲克劳林注射液获批上市仍存在不确定性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"002923":1},"content_text":"Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) has issued an announcement regarding significant stock price fluctuations, stating that the company currently possesses a Class 1 innovative chemical drug, Norcoclaurine Hydrochloride Injection (Specification: 2ml:2.5mg), along with its active pharmaceutical ingredient, and the drug evaluation process is proceeding in an orderly manner.\nInnovative drug development is characterized by long cycles, substantial investment, and high risks; consequently, uncertainties remain regarding whether the drug will ultimately gain market approval, the timeline for any potential approval, and its subsequent production and sales performance post-launch, and it is not expected to significantly impact the company's financial performance in the short term.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}